期刊
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
卷 27, 期 3, 页码 346-349出版社
SPRINGER VERLAG
DOI: 10.1007/s002590050044
关键词
[I-123]FP-CIT; dopamine transporter imaging; animal studies; dopaminergic medication; Parkinson's disease; single-photon emission tomography
The recently developed radioligand [I-123]FP-CIT is suitable for clinical single-photon emission tomography (SPET) imaging of the dopamine (DA) transporter in vivo. To date it has remained unclear whether dopaminergic medication influences the striatal [I-123]FP-CIT binding. The purpose of this study was to investigate the influence of this medication on [I-123]FP-CIT binding in the brain. We used an animal model in which we administered dopaminomimetics, antipsychotics and an antidepressant. In vivo [I-123]FP-CIT binding to the DA and serotonin transporters was evaluated after subchronic and acute administration of the drugs. The administered medication induced small changes in striatal [I-123]FP-CIT binding which were not statistically significant. As expected, the DA reuptake blocker GBR 12,909 induced a significant decrease in [I-123]FP-CIT binding. [I-123]FP-CIT binding in the serotonin-rich hypothalamus was decreased only after acute administration of fluvoxamine, The results of this study suggest that dopaminergic medication will not affect the results of DA transporter SPET imaging with [I-123]FP-CIT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据